Table 2.
Observed proportions experiencing study outcomes, with general estimating equation risk differences (viral suppression) and generalized linear model risk differences (secondary outcomes).
| HIV Clinic-Based Buprenorphine |
MMT Referral | Risk Difference RD (95% CI) |
|
|---|---|---|---|
| Viral suppression | |||
| 0 months | 97/140 (69.3%) | 92/140 (65.7%) | - |
| 6 months | 73/92 (79.3%) | 100/110 (90.9%) | −0.12 (−0.21, −0.02) |
| 12 months | 74/91 (81.3%) | 99/107 (92.5%) | –0.11 (−0.21, −0.02) |
| ART receipt | |||
| 0 months | 99/136 (72.8%) | 92/135 (68.1%) | - |
| 3 months | 116/134 (86.6%) | 122/134 (91.0%) | −0.01 (−0.03, 0.01) |
| 6 months | 99/133 (74.4%) | 115/131 (87.8%) | −0.08 (−0.15, −0.01) |
| 9 months | 103/131 (78.6%) | 114/131 (87.0%) | −0.05 (−0.10, 0.01) |
| 12 months | 108/128 (84.4%) | 116/131 (88.5%) | −0.02 (−0.05, 0.01) |
| ART adherence | |||
| 0 months | 26/96 (27.1%) | 25/95 (26.3%) | - |
| 3 months | 29/101 (28.7%) | 27/106 (25.5%) | 0.003 (−0.13, 0.13) |
| 6 months | 33/92 (35.9%) | 33/112 (29.5%) | 0.05 (−0.11, 0.21) |
| 9 months | 29/92 (31.5%) | 32/118 (27.1%) | 0.04 (−0.10, 0.18) |
| 12 months | 29/104 (27.9%) | 31/114 (27.2%) | 0.0001 (−0.13, 0.13) |
| HIV Clinic Visit in past 3 months | |||
| 0 months | - | - | - |
| 3 months | 121/140 (86.4%) | 123/141 (87.2%) | −0.0001 (−0.01, 0.01) |
| 6 months | 114/140 (81.4%) | 107/141 (75.9%) | −0.02 (−0.07, 0.02) |
| 9 months | 116/140 (82.9%) | 100/141(70.9%) | −0.07 (−0.15, 0.01) |
| 12 months | 118/140 (84.3%) | 111/141 (78.7%) | −0.02 (−0.05, 0.01) |
| Retention on medication | |||
| 0 months | - | - | |
| 3 months | 127/141 (90.1%) | 101/140 (72.1%) | 0.06 (0.003, 0.11) |
| 6 months | 85/141 (60.3%) | 94/140 (67.1%) | −0.10 (−0.26, 0.06) |
| 9 months | 63/141 (44.7%) | 92/140 (65.7%) | −0.43 (−0.66, −0.20) |
| 12 months | 57/141 (40.4%) | 91/140 (65.0%) | −0.53 (−0.75, −0.31) |
| Heroin use: UDS | |||
| 0 months | 141/141 (100%) | 140/140 (100%) | - |
| 3 months | 81/117 (69.2%) | 106/122 (86.9%) | −0.14 (−0.25, −0.04) |
| 6 months | 62/101 (61.4%) | 81/114 (71.1%) | −0.12 (−0.29, 0.06) |
| 9 months | 60/97 (61.9%) | 88/117 (75.2%) | −0.13 (−0.29, 0.03) |
| 12 months | 66/98 (67.3%) | 72/110 (65.5%) | 0.05 (−0.12, 0.21) |
| Heroin use: ASI Self Report | |||
| 0 months | 141/141 (100%) | 140/140 (100%) | - |
| 3 months | 100/124 (80.6%) | 80/117 (68.4%) | −0.12 (−0.24, −0.005) |
| 6 months | 85/118 (72.0%) | 65/103 (63.1%) | –0.12 (−0.29, 0.05) |
| 9 months | 86/119 (72.3%) | 58/100 (58.0%) | −0.18 (−0.36, 0.001) |
| 12 months | 67/115 (58.3%) | 64/107 (59.8%) | 0.05 (−0.16, 0.26) |